TCR peptide therapy in human autoimmune diseases

Neurochemical Research

Volumn 26, Issue 6, 2001, Pages 713-730

  Vandenbark, Arthur A ^a,b,c   Morgan, Elizabeth ^d   Bartholomew, Richard ^d   Bourdette, Dennis ^a,b   Whitham, Ruth ^a,b   Carlo, Dennis ^d   Gold, Daniel ^e   Hashim, George ^f   Offner, Halina ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Orchestra Therapeutics Inc   (United States)

^e Favrille Inc   (United States)

^f NONE

Author keywords

Autoimmune diseases; Immunotherapy; Regulatory cytokines; T cell receptor

Indexed keywords

FREUND ADJUVANT; T CELL RECEPTOR PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE RECEPTOR GENE; TH1 CELL; TH2 CELL;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS; PSORIASIS; RECEPTORS, ANTIGEN, T-CELL;

EID: 0034871273     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010951706830     Document Type: Article

References (105)

1. T cell receptor peptides in treatment of autoimmune disease: Rationale and potential
2. Genes of the T-cell antigen receptor in normal and malignant T cells
3. T-cell antigen receptor genes and T-cell recognition
4. Autoimmunity, microbial immunity and the immunological homunculus
5. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis
6. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides
7. The problem of presentation of T cell receptor peptides by activated T cells
8. Treatment of multiple sclerosis with T cell receptor peptides: Results of a double-blind pilot trial
9. MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR VB CDR2 peptides: Comparison with myelin basic protein-specific T cells
10. Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis
11. Human T cell autoimmunity against myelin basic protein: CD4 + cells recognizing epitopes of the T cell receptor B chain from a myelin basic protein-specific T cell clone
12. Immunity to T cell receptor peptides in multiple sclerosis. II. T cell recognition of Vβ5.2 and Vβ6.1 CDR2 peptides
13. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells
14. Interleukin-10 prevents experimental allergic encephalomyelitis in rats
15. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis
16. Therapeutic application of T cell receptor peptides
17. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions
18. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL)and anergizes T cells specifically recognized by these CTL
19. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination
20. Functional characterization of CD8 anti-clonotypic T cells from MS patients treated with T cell vaccination
21. Human CD8+ T lymphocyte clones specific for T cell receptor Vβ families expressed on autologous CD4+ T cells
22. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor
23. Human TCR as antigen: Homologies and potentially cross-reactive HLA-DR2-restricted epitopes within the AV and BV CDR2 loops
24. Preferential T cell receptor β-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis
25. T cell receptor V genes in multiple sclerosis: Increased use of TCRAV8 and TCRBV5 in MBP-specific clones
26. On the immunopathology of plaque development and repair in multiple sclerosis
27. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma
28. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls
29. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis
30. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis
31. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects
32. The small heat-shock protein a-B-crystallin as candidate autoantigen in multiple sclerosis
33. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein
34. Direct ex vivo analysis of activated fas-sensitive autoreactive T cells in human autoimmune disease
35. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis
36. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations
37. T cells responsive to myelin basic protein in patients with multiple sclerosis
38. Frequency of MBP and MBP peptide-reactive T cells in the HPRT mutant T-cell population of MS patients
39. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides
40. Episodic changes in T cell frequencies to myelin basic protein in patients with multiple sclerosis
41. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
42. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
43. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination
44. Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice
45. Species-restricted encephalitogenic determinants
46. Experimental autoimmune encephalomyelitis (EAE) mediated by cell lines: Process of selection of lines and characterization of the cells
47. Induction of experimental allergic encephalomyelitis by myelin proteolipid protein specific T cell clones and synthetic peptides
48. Lymphocytes from SJL/J mice immunized with spinal cord resP0nd selectively to a peptide of proteolipid protein and transfer relapsing demyelinating EAE
49. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice
50. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat
51. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone
52. HLA-linked and unlinked determinants of multiple sclerosis
53. Multiple sclerosis and HLA-DQw1
54. Multiple sclerosis and the HLA-D region: Linkage and association studies
55. T-cell receptor genes. Germline polymorphisms and genetic susceptibility to demyelinating diseases
56. The V-region disease hypothesis: Evidence from autoimmune encephalomyelitis
57. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis
58. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis
59. The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease
60. Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis
61. Vaccination with BV8S2 protein amplifies TCR specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice
62. Vaccination with a recombinant Va domain of a TCR prevents the development of collagen-induced arthritis
63. Natural immunodominant and EAE-protective determinants within the Lewis rat V 8.2 sequence include CDR2 and framework 3 idiotopes
64. Immunodominant framework region 3 peptide from TCR VB8.2 chain controls murine experimental autoimmune encephalomyelitis
65. CDR1 T-cell receptor β-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions
66. TCR usage in human and experimental demyelinating disease
67. Restricted T-cell receptor Vβ gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: Predominant genes vary in individuals
68. Selection of T-cell receptor V-D-J gene rearrangements with specificity for a MBP peptide in brain lesions of MS
69. Expansion of a recurrent VB5.3+ T-cell population in newly diagnosed and untreated HLA-DR2 multiple sclerosis patients
70. Characterization of T-cell receptor Vβ usage in the brain of a subject with multiple sclerosis
71. Lack of over-expression of T cell receptor VB5.2 in myelin basic protein-specific T cell lines derived from HLADR2 positive multiple sclerosis patients and controls
72. Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity
73. Activated suppressor cell dysfunction in progressive multiple sclerosis
74. Comparison of T8 + cell-mediated suppressor and cytotoxic functions in multiple sclerosis
75. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis
76. Activated suppressor cell function in multiple sclerosis-clinical correlations
77. Diminished frequency of IL-10 secreting TCR BV5S2 peptide-reactive T cells in MS
78. Immunity to T cell receptor peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides
79. Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity determining region 2 peptides from disease-associated T cell receptor BV genes
80. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVB6 CDR2 peptide
81. A common T cell receptor V-D-J-sequence in VB13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis
82. Rheumatoid arthritis: Pathophysiology and implications for therapy
83. Do nonimmunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis?
84. MHC class II molecules and autoimmunity
85. The molecular basis of susceptibility to rheumatoid arthritis
86. T-cells in the pathogenesis of rheumatoid arthritis: Villains or accomplices
87. The role of T cells in the immunopathogenesis of rheumatoid arthritis: New perspectives
88. T cells as primary players in rheumatoid arthritis
89. Evidence for the effects of a superantigen in rheumatoid arthritis
90. Limited T-cell receptor β-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis
91. Residues of the variable region of the T-cell receptor β-chain that interact with S. aureus toxin superantigens
92. Identification of the region of T cell receptor β chain that interacts with the self-superantigen Mis-1 +
93. Biologic agents for treating rheumatoid arthritis: Concepts and progress
94. Editorial: Targeting the T cell receptor in rheumatoid arthritis
95. Skewed T-cell receptor variable gene usage in the synovium of early and chronic rheumatoid arthritis patients and persistence of clonally expanded T cells in a chronic patient
96. Increased frequency of Vβ 17-positive T cells in patients with rheumatoid arthritis
97. Vβ17 T cell receptor peptide vaccination in rheumatoid arthritis: Results of a phase I dose escalation study
98. T cell receptor peptide vaccination in rheumatoid arthritis. A placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides
99. Lymphocyte activation in the pathogenesis of psoriasis
100. Pulling the trigger on psoriasis
101. Dermal injection of immunocytes induces psoriasis
102. CD8+ T cells in psoriatic lesions preferentially use T cell receptors Vβ3 and/or Vβ13.1 genes
103. CD8+ T-cells in psoriatic lesions preferentially use T-cell receptors Vβ3 and/or Vβ13.1 genes
104. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
105. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy